Findings

What do systematic reviews say?

24 questions · 25 findings · 2 reviews · Gynaecology and Fertility

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3 · 12%GRADE not reported 0 · 0%Very low 12 · 48%Low 9 · 36%Moderate 1 · 4%High 0 · 0%

GnRHa treatment vs no treatment

No studies included for any outcomes · women with endometriosis

The review found no eligible studies for this question.

1 finding from 1 review

Gonadotropin‐releasing hormone analogues for endometriosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

GnRHa treatment vs danazol

Relief of pain · patients with pain associated with endometriosis

1 finding from 1 review

Gonadotropin‐releasing hormone analogues for endometriosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 41 participants
Very low

GnRHa treatment vs danazol

Relief of overall pain ‐ reported as pelvic pain ‐ 3 months · patients with pain associated with endometriosis

1 finding from 1 review

Gonadotropin‐releasing hormone analogues for endometriosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 41 participants
Very low

GnRHa treatment vs danazol

Relief of overall pain ‐ reported as dysmenorrhoea ‐ 6 months · patients with pain associated with endometriosis

1 finding from 1 review

Gonadotropin‐releasing hormone analogues for endometriosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 41 participants
Very low

GnRHa treatment vs danazol

Relief of overall pain ‐ reported as pelvic induration ‐ 6 months · patients with pain associated with endometriosis

1 finding from 1 review

Gonadotropin‐releasing hormone analogues for endometriosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 41 participants
Very low

GnRHa treatment vs danazol

Relief of overall pain ‐ reported as pelvic tenderness ‐ 6 months · patients with pain associated with endometriosis

1 finding from 1 review

Gonadotropin‐releasing hormone analogues for endometriosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 41 participants
Very low

GnRHa treatment vs intra‐ uterine progestogen device

No studies included with only low risk of bias · patients with pain associated with endometriosis

The review found no eligible studies for this question.

1 finding from 1 review

Gonadotropin‐releasing hormone analogues for endometriosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

GnRHa treatment vs placebo

Relief of overall pain ‐ reported as pelvic pain ‐ 3 months · women with endometriosis

GnRHas may leads to higher relief of overall pain ‐ reported as pelvic pain ‐ 3 months compared with placebo (low certainty).

1 finding from 1 review

Gonadotropin‐releasing hormone analogues for endometriosis 2023 · Cochrane Headline outcomes only
RR 2.14 [1.41, 3.24]
1 study · 87 participants
Low

GnRHa treatment vs placebo

Relief of painful symptoms ‐ Dysmenorrhoea · women with endometriosis

GnRHas may leads to higher relief of overall pain ‐ reported as dysmenorrhoea ‐ 3 months compared with placebo (low certainty).

1 finding from 1 review

Gonadotropin‐releasing hormone analogues for endometriosis 2023 · Cochrane Headline outcomes only
RR 2.25 [1.59, 3.16]
1 study · 87 participants
Low

GnRHa treatment vs placebo

Relief of overall pain ‐ reported as dyspareunia ‐ 3 months · women with endometriosis

GnRHas may leads to higher relief of overall pain ‐ reported as dyspareunia ‐ 3 months compared with placebo (low certainty).

1 finding from 1 review

Gonadotropin‐releasing hormone analogues for endometriosis 2023 · Cochrane Headline outcomes only
RR 2.21 [1.39, 3.54]
1 study · 87 participants
Low

GnRHa treatment vs placebo

Relief of overall pain ‐ reported as pelvic tenderness ‐ 6 months · women with endometriosis

GnRHas may leads to higher relief of overall pain ‐ reported as pelvic tenderness scores‐ 3… compared with placebo (low certainty).

1 finding from 1 review

Gonadotropin‐releasing hormone analogues for endometriosis 2023 · Cochrane Headline outcomes only
RR 2.28 [1.48, 3.5]
1 study · 87 participants
Low

GnRHa treatment vs placebo

Relief of overall pain ‐ reported as pelvic induration ‐ 6 months · women with endometriosis

GnRHas showed no clear difference in relief of overall pain ‐ reported as pelvic induration scores ‐ 3… compared with placebo (low certainty).

1 finding from 1 review

Gonadotropin‐releasing hormone analogues for endometriosis 2023 · Cochrane Headline outcomes only
RR 1.07 [0.64, 1.79]
1 study · 87 participants
Low

GnRHa treatment vs analgesics

No studies included for any outcomes · patients with pain associated with endometriosis

The review found no eligible studies for this question.

1 finding from 1 review

Gonadotropin‐releasing hormone analogues for endometriosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

GnRHa treatment vs danazol

Relief of overall pain ‐ reported as pelvic tenderness, partly resolved ‐ 6 months · patients with pain associated with endometriosis

It is very uncertain whether gnRHas changes relief of overall pain ‐ reported as pelvic tenderness, partly… compared with danazol (very low certainty).

1 finding from 1 review

Gonadotropin‐releasing hormone analogues for endometriosis 2023 · Cochrane Headline outcomes only
RR 1.15 [0.49, 2.73]
1 study · 41 participants
Very low

GnRHa treatment vs danazol

Relief of overall pain ‐ reported as pelvic tenderness, complete resolved ‐ 6 months · patients with pain associated with endometriosis

It is very uncertain whether gnRHas changes relief of overall pain ‐ reported as pelvic tenderness, complete… compared with danazol (very low certainty).

1 finding from 1 review

Gonadotropin‐releasing hormone analogues for endometriosis 2023 · Cochrane Headline outcomes only
RR 1.1 [0.67, 1.81]
1 study · 41 participants
Very low

GnRHa treatment vs no treatment

Relief of painful symptoms ‐ Dysmenorrhoea · patients with pain associated with endometriosis

GnRHas may leads to higher relief of painful symptoms ‐ Dysmenorrhoea compared with no treatment (low certainty).

1 finding from 1 review

Gonadotrophin‐releasing hormone analogues for pain associated with endometriosis 2010 · Cochrane Headline outcomes only
RR 3.93 [1.37, 11.28]
1 study · 35 participants
Low

GnRHa treatment vs placebo

Relief of painful symptoms ‐ pelvic tenderness · patients with pain associated with endometriosis

GnRHas may leads to higher relief of painful symptoms ‐ pelvic tenderness compared with placebo (low certainty).

1 finding from 1 review

Gonadotrophin‐releasing hormone analogues for pain associated with endometriosis 2010 · Cochrane Headline outcomes only
RR 4.17 [1.62, 10.68]
1 study · 49 participants
Low

GnRHa treatment vs placebo

Pain score ‐ Overall at 4 weeks · patients with pain associated with endometriosis

1 finding from 1 review

Gonadotrophin‐releasing hormone analogues for pain associated with endometriosis 2010 · Cochrane Headline outcomes only
no estimate extracted
1 study · 120 participants
Low

GnRHa treatment vs danazol

Relief of painful symptoms ‐ Dysmenorrhoea · patients with pain associated with endometriosis

It is very uncertain whether gnRHas changes relief of painful symptoms ‐ Dysmenorrhoea compared with danazol (very low certainty).

1 finding from 1 review

Gonadotrophin‐releasing hormone analogues for pain associated with endometriosis 2010 · Cochrane Headline outcomes only
RR 0.98 [0.92, 1.04]
7 studies · 666 participants
Very low

GnRHa treatment vs danazol

Overall resolution ‐ Overall resolution/improvement · patients with pain associated with endometriosis

GnRHas may leads to higher overall resolution ‐ Overall resolution/improvement compared with danazol (low certainty).

1 finding from 1 review

Gonadotrophin‐releasing hormone analogues for pain associated with endometriosis 2010 · Cochrane Headline outcomes only
RR 1.1 [1.01, 1.21]
9 studies · 1046 participants
Low